To ask His Majesty's Government what assessment they have made of (1) the level of unmet need of immunocompromised patients for protection against COVID-19, and (2) whether the MHRA has sufficient staff so that it can appropriately prioritise regulatory decisions in support of such patients.
Answered on
2 April 2024
As set out in the Living with COVID-19 Strategy, the Government and the UK Health Security Agency will continue to communicate to people most vulnerable to COVID-19 about available clinical interventions, including vaccination and treatments, as well as testing and public health advice.
All individuals aged six months old or above who are immunosuppressed were offered a vaccination in the Autumn 2023 COVID-19 vaccination programme, along with those in other clinical risk groups. The immunosuppressed group will be offered a further dose as part of the spring programme announced in February, that is being rolled out in England from mid-April. This follows the Joint Committee on Vaccination and Immunisation’s advice that those who are immunosuppressed are at particular risk of serious disease from COVID-19.
The Medicines and Healthcare products Regulatory Agency (MHRA) is looking at novel and standard ways to develop staff capability and expertise. New assessor capacity is being supplemented with an additional fixed-term resource of appropriately experienced and qualified specialists, to support the training and supervision of new staff. The MHRA also continues to recruit to additional roles in its assessment teams.